Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$79.59
-$0.05(-0.07%)
At close: 4:00 PM EDT
$79.59
-$0.05(-0.07%)
Day’s Range― - ―
52-Week Range$41.50 - $166.48
Previous CloseN/A
Volume220.30K
Average Volume (3M)1.25M
Market Cap
$6.28B
Enterprise Value$2.17B
Total Cash (Recent Filing)$861.61M
Total Debt (Recent Filing)$91.31M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Nov 18, 2026EPS Estimate
-2.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.75
Shares Outstanding44,666,233
10 Day Avg. Volume1,303,206
30 Day Avg. Volume1,250,205
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue13.15
Enterprise Value/Gross Profit-121.44
Enterprise Value/Ebitda-5.81
Forecast
1Y Price Target
$118.44Price Target Upside48.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-9.62
Revenue Forecast (FY)$180.80M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Test-volume GrowthStrong growth in both revenue and test volume indicates increasing customer adoption of Galleri and expanding commercial reach. Continued volume gains can improve operating leverage, support broader provider engagement, and strengthen the company’s position in the emerging MCED screening market.
Differentiated Clinical PerformanceThe reported clinical profile may provide a meaningful differentiation from competing MCED tests, particularly through fewer false positives and useful cancer-signal detection. Stronger evidence can support physician confidence, regulatory review, adoption, and future coverage discussions over time.
Strong Liquidity And Low LeverageSubstantial liquidity and very low leverage give GRAIL flexibility to fund clinical work, regulatory activity, and commercial expansion without relying heavily on debt. The balance sheet provides time to pursue scale and improve economics while the company works toward sustainable cash generation.
Bears Say
Large Losses And Negative Gross ProfitGRAIL remains far from profitability despite strong revenue growth, with negative gross profit and operating losses that are very large relative to sales. This weak cost structure may require prolonged investment and makes future earnings dependent on substantial margin improvement and scale.
Persistent Cash BurnDeeply negative operating and free cash flow show that the current business model is not yet self-funding. Continued cash consumption can reduce financial flexibility over time and increase dependence on existing reserves or external capital unless volume growth translates into durable contribution-margin gains.
Clinical And Regulatory Execution RiskThe missed NHS-Galleri primary endpoint weakens an important clinical validation narrative, even though secondary results were positive. Combined with uncertainty around the FDA advisory process, this could delay approval, broadened access, reimbursement progress, and the expected commercial ramp.
GRAIL Inc News
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $41.50 and its highest was $166.47 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $6.28B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Nov 18, 2026 which is in 37 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Aug 05, 2026. The company reported -$2.56 earnings per share for the quarter, beating the consensus estimate of -$2.656 by $0.096.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Undervalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -2.5.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 44,666,233 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$2.56 in its last earnings report, beating expectations of -$2.656. Following the earnings report the stock price went down -14.532%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$118.44 (48.82% Upside)
$118.44 (48.82% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 834.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 22.2%
Last 30 Days ▲ 22.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.63%
12-Months-Change
Fundamentals
Return on Equity
-15.88%
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GRAIL Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$118.44
▲(48.82% Upside)
Technical Analysis
Ownership Overview
11.06% Insiders
12.00% Mutual Funds
0.41% Other Institutional Investors
61.10% Public Companies and
Individual Investors